CN101190894A - Fatty acid synthetic enzyme inhibitor and medical preparation use thereof - Google Patents
Fatty acid synthetic enzyme inhibitor and medical preparation use thereof Download PDFInfo
- Publication number
- CN101190894A CN101190894A CNA2006101147935A CN200610114793A CN101190894A CN 101190894 A CN101190894 A CN 101190894A CN A2006101147935 A CNA2006101147935 A CN A2006101147935A CN 200610114793 A CN200610114793 A CN 200610114793A CN 101190894 A CN101190894 A CN 101190894A
- Authority
- CN
- China
- Prior art keywords
- oxo
- carboxylic acid
- benzyloxies
- pyrroles
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract description 18
- 239000000194 fatty acid Substances 0.000 title claims abstract description 18
- 229930195729 fatty acid Natural products 0.000 title claims abstract description 18
- 150000004665 fatty acids Chemical class 0.000 title claims abstract description 17
- 229940125532 enzyme inhibitor Drugs 0.000 title 1
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 67
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- -1 CF 3 Chemical group 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 238000010992 reflux Methods 0.000 claims description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- GYBMSOFSBPZKCX-UHFFFAOYSA-N sodium;ethanol;ethanolate Chemical compound [Na+].CCO.CC[O-] GYBMSOFSBPZKCX-UHFFFAOYSA-N 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 7
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 6
- 238000007259 addition reaction Methods 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 6
- 230000005494 condensation Effects 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 claims description 6
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 6
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 150000003141 primary amines Chemical class 0.000 claims description 6
- 238000007127 saponification reaction Methods 0.000 claims description 6
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 5
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 235000011150 stannous chloride Nutrition 0.000 claims description 4
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 claims description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 150000004678 hydrides Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 5
- 102000003960 Ligases Human genes 0.000 abstract description 3
- 108090000364 Ligases Proteins 0.000 abstract description 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000004494 ethyl ester group Chemical group 0.000 description 135
- 238000005160 1H NMR spectroscopy Methods 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 239000013078 crystal Substances 0.000 description 35
- 239000007787 solid Substances 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 26
- 239000012043 crude product Substances 0.000 description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 24
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 22
- 229960004217 benzyl alcohol Drugs 0.000 description 20
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 235000019445 benzyl alcohol Nutrition 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000001953 recrystallisation Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 11
- 235000008504 concentrate Nutrition 0.000 description 11
- 229960000935 dehydrated alcohol Drugs 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 229960004756 ethanol Drugs 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101710172177 Fasciclin-2 Proteins 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000003810 ethyl acetate extraction Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 101710172176 Fasciclin-1 Proteins 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003233 pyrroles Chemical class 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- LDIFYZGCGRNXGX-UHFFFAOYSA-N 1-chloro-2-[(4-nitrophenoxy)methyl]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC1=CC=CC=C1Cl LDIFYZGCGRNXGX-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000003570 biosynthesizing effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- RPIHHCBXTMTVCU-UHFFFAOYSA-N phenylmethanol Chemical compound OCC1=CC=CC=C1.OCC1=CC=CC=C1 RPIHHCBXTMTVCU-UHFFFAOYSA-N 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 1
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- GQEZCXVZFLOKMC-UHFFFAOYSA-N 1-hexadecene Chemical compound CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YKNZTUQUXUXTLE-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(C(F)(F)F)=C1 YKNZTUQUXUXTLE-UHFFFAOYSA-N 0.000 description 1
- HBOPVJJZFWIXOS-UHFFFAOYSA-M [Na][Zn]Cl Chemical compound [Na][Zn]Cl HBOPVJJZFWIXOS-UHFFFAOYSA-M 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940008126 aerosol Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- DCAYPVUWAIABOU-UHFFFAOYSA-N alpha-n-hexadecene Natural products CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940055036 mycobacterium phlei Drugs 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000010458 rotten stone Substances 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
The invention relates to a compound of a general formula I, which is capable of inhibiting synthetase of fatty acid FabH and the medical salt or hydrate thereof. The definition of each substitute group of the general formula I is stated in the manual book. The invention also relates to a preparation method of the compound of the general formula I and comprises medical compositions of the compound of the general formula I or the medical salt or hydrate thereof as well as the application of the compound used for preparing an inhibitor for the synthetase of fatty acid. The compound is also applicable in medical treatment of bacterial infection.
Description
Technical field
The present invention relates to pyrrole derivative and pharmacologically acceptable salt thereof as fatty acid sythetase inhibitor (FabH), its preparation method contain their pharmaceutical composition, and described compound is used to prepare the purposes of fatty acid sythetase inhibitor.
Background technology
In all biological organisms, fatty acid biological synthetic (fatty acidbiosynthesis) all is an essential process.Prokaryotic organism and Eukaryotic fatty acid biological are synthetic be by fatty acid synthetase (fatty acid synthase, FAS) catalysis is finished, although their route of synthesis basically identical, the structure of biosynthesizing device but has nothing in common with each other.Catalysis fatty acid biological synthetic enzyme cording has two types (FAS I and FAS II).FAS I is present in Mammals and the yeast, and wherein whole enzymic activitys all is coded in respectively on the polypeptide chain, and each step lipid acid building-up reactions all is to be finished by this big proteic difference in functionality territory catalysis.FAS II is present in bacterium and the plant, and it is made up of a series of little isolating albumen, and each step lipid acid building-up reactions is all finished by distinct single functional enzyme catalysis.The uniqueness of mycobacterium just is that it has FAS I and FAS II simultaneously, and FAS I relates to the biosynthesizing of basic lipid acid, and FAS II relates to the synthetic of compound cell envelope fat (as mycolic acid).Therefore, selectivity suppresses the inhibitor of the single functional enzyme of FAS II system, might develop into extensive pedigree antibiotic (Payne DJ, Warren PV, Holmes DJ, etal.Drug Discov Develop, 2001,6 (10): 537-544; Heath RJ, WhitebSW, Rock CO.Prog Lipid Res, 2001,40:467-497).
Single functional enzyme FabH of FAS II system is a substrate with acetyl-CoA, is that the synthetic carbochain of lipid acid prolongs the round-robin initiation factor, extensively is present in the bacterium.Simultaneously, this round-robin final product palmityl-ACP produces feedback inhibition again to FabH.Therefore, FabH is important fatty acid biological synthetic enzyme, simultaneously the still crucial point of adjustment in the whole route of synthesis.As seen, FabH plays a part necessary in the bacterium fatty acid biological is synthetic and regulates (Heath RJ, Rock CO.J Biol Chem, 1996,271 (4): 1833-1836; Revill WP, Bibb MJ, ScheuAK, et al.J Bacteriol, 2001,183:3526-3530).
Because the chemical sproof appearance of germ presses for the exploitation novel antibacterial medicine different with existing drug mechanism.Still do not act on the antimicrobial drug of fatty acid biosynthetic pathway on the market, therefore, fatty acid sythetase inhibitor is expected to develop into novel extensive pedigree antibiotic.
Summary of the invention
According to an aspect of the present invention, the present invention relates to compound or its all possible isomer or the pharmacologically acceptable salt or the hydrate of general formula I:
Wherein:
Q is CH
2O or NH;
R
1Be aryl;
R
2Be aryl, C
3-10Alkyl or C
4-8Cycloalkyl.
Term used herein " aryl " is meant phenyl, or by hydroxyl, halogen, nitro, CF
3, methylene-dioxy, C
1-6Alkyl, C
1-6Substituting groups such as alkoxyl group one or polysubstituted phenyl.
Term used herein " C
3-10Alkyl " be meant straight or branched alkyl with 3-10 carbon atom, it includes but not limited to n-propyl, sec.-propyl, normal-butyl, sec-butyl, isobutyl-, the tertiary butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl etc.Optional hydroxyl, carboxyl, halogen and the C of being selected from of this group
1-6The substituting group of alkoxyl group replaces.
Term used herein " cycloalkyl " is meant the ring with 4-8 carbon atom, and it includes but not limited to cyclopentyl, cyclohexyl, suberyl, ring octyl group etc.
Compound of the present invention can comprise one or more asymmetric centers, and can exist with racemic modification and optical activity form.All these racemic modifications or enantiomorph include within the scope of the present invention.
Compounds more of the present invention can form solvate in this case with solvent crystallization or recrystallization, and they include within the scope of the present invention.
Compound of the present invention is purpose with medicinal, is appreciated that they preferably provide with pure form, at least 60% purity for example, and more suitably 75%, better 85%, best at least 98% purity (% is meant weight percent).
According to another aspect of the present invention, the present invention relates to contain the pharmaceutical composition of above-mentioned compound of Formula I, it comprises compound or its all possible isomer or the pharmacologically acceptable salt or the hydrate of general formula I of the present invention, and at least a pharmaceutically acceptable carrier or vehicle.
According to another aspect of the present invention, the invention still further relates to the method for the above-mentioned compound of Formula I of preparation.
According to a further aspect of the present invention, the present invention relates to the purposes that described compound is used to prepare fatty acid sythetase inhibitor, this fatty acid sythetase inhibitor can be used as the antimicrobial drug of treatment gram-positive microorganism and negative bacterium infection.
The invention still further relates to treatment animal and human's gram-positive microorganism and the method that negative bacterium infects, this method comprises the animal that these needs are arranged, the The compounds of this invention that comprises the human therapy significant quantity.
Preferred The compounds of this invention is selected from:
1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-hexyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(2-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(3-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(3-trifluoromethyl-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(4-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-benzyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(3-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(2-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-cyclohexyl methyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(3-trifluoromethyl-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(4-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-pyrrolin-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-1-(3-trifluoromethyl-benzyl)-2,5-pyrrolin-3-carboxylic acid;
1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-pyrrolin-3-carboxylic acid;
1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-pyrrolin-3-carboxylic acid; With
4-[4-(2,6-two chloro-benzyloxies)-aniline]-1-octyl group-5-oxo-2,5-pyrrolin-3-carboxylic acid;
Or its pharmacologically acceptable salt or hydrate.
According to the present invention, wherein Q is CH
2The formula of O (I) compound can be prepared by following scheme 1 described synthetic route:
Scheme 1
a)NaH，DMF；b)NaBH
4，CH
3OH；c)C
2H
5ONa，C
2H
5OH；d)Ph
3P，DEAD，THF；e)NaOH，CH
3OH。
Specifically, with R wherein
1Define as above-mentioned general formula I, X is the formula R of halogen
1CH
2X benzyl halide (scheme 1-1) and p-Hydroxybenzaldehyde (scheme 1-2) are raw material, handle in sodium hydride/DMF and stir (5-0 ℃, 0.5 hour), generate compound scheme 1-3; Then, with hydride reducer (as sodium borohydride) reduction scheme 1-3 in solvent (as methyl alcohol), obtain compound 4 (scheme 1-4); Under rare gas element such as nitrogen protection, make formula R
2CH
2Addition reaction takes place in X primary amine (scheme 1-5) and ethyl propenoate (scheme 1-6) under stirring at room, under reflux temperature condensation reaction takes place with oxalic acid diethyl ester (scheme 1-7) then in sodium ethylate-ethanol alkaline system, through acidic hydrolysis, make pyrrole derivative 8 (scheme 1-8) again.Utilize catalyzer (as triphenyl phosphorus and diethylazodicarboxylate) to make compound 4 and compound 8 in solvent (as THF), carry out condensation and slough 1 molecular water, make compound 9 (scheme 1-9); Make compound 9 and alkali (as sodium hydroxide) saponification in solvent (as methyl alcohol), obtain wherein R
1And R
2As the defined compound of above-mentioned general formula I (scheme 1-10).
Wherein Q is that formula (I) compound of NH can be prepared by the synthetic route described in the following scheme 2:
Scheme 2
a)C
2H
5ONa，C
2H
5OH；b)SnCl
2，C
2H
5OH；c)C
2H
5ONa，C
2H
5OH；d)AcOH；e)NaHCO
3，THF，C
2H
5OH。
Specifically, under reflux temperature, make 2,6-dichloro bromobenzyl (scheme 2-1) and paranitrobenzaldehyde (scheme 2-2) react in sodium ethylate-ethanol alkaline system, generate compound 3 (scheme 2-3); Then, with reductive agent (as tin protochloride) reducing compound 3 in solvent (as ethanol), obtain compound 4 (scheme 2-4); Under rare gas element such as nitrogen protection, make formula R
2CH
2Addition reaction takes place in X primary amine (scheme 2-5) and ethyl propenoate (scheme 2-6) under stirring at room, under reflux temperature condensation reaction takes place with oxalic acid diethyl ester (scheme 2-7) then in sodium ethylate-ethanol alkaline system, through acidic hydrolysis, make pyrrole derivative 8 (scheme 2-8) again.Utilize catalyzer (as acetic acid) to make compound 4 and compound 8 condensations and slough 1 molecular water, make compound 9 (scheme 2-9); Make compound 9 and alkali (as sodium bicarbonate) saponification in solvent (as THF and ethanol), obtain wherein R
2Compound of Formula I (scheme 2-10) as defined above.
Therefore, the preparation method of general formula of the present invention (I) compound can be summarized as follows:
For Q wherein is CH
2The formula of O (I) compound, this method may further comprise the steps:
(1) with R wherein
1As above general formula I defines, X is the formula R of halogen
1CH
2X benzyl halide and p-Hydroxybenzaldehyde are raw material, handle in sodium hydride/DMF under-5-0 ℃ and stir 0.5 hour; In solvent such as methyl alcohol, reduce the scheme products therefrom with hydride reducer such as sodium borohydride then;
(2) under rare gas element such as nitrogen protection, make wherein R
2The as above defined formula R of general formula I
2CH
2Addition reaction takes place in X primary amine and ethyl propenoate under stirring at room, under reflux temperature condensation reaction takes place with oxalic acid diethyl ester in sodium ethylate-ethanol alkaline system then, make again product experience acidic hydrolysis;
(3) utilize catalyzer such as triphenyl phosphorus and diethylazodicarboxylate to make step (1) and step (2) product carry out condensation and slough 1 molecular water in solvent such as THF, and make it the saponification in solvent such as methyl alcohol with alkali such as sodium hydroxide, obtaining wherein, Q is CH
2O, and R
1And R
2Compound of Formula I as defined above;
Perhaps,
For Q wherein is formula (I) compound of NH, and this method may further comprise the steps:
(1) under reflux temperature, make 2,6-dichloro bromobenzyl and paranitrobenzaldehyde react in sodium ethylate-ethanol alkaline system, then, reduce products therefrom with reductive agent such as tin protochloride in solvent such as ethanol;
(2) under rare gas element such as nitrogen protection, make wherein R
2The as above definition R of general formula I institute
2CH
2Addition reaction takes place in X primary amine and ethyl propenoate under stirring at room, under reflux temperature condensation reaction takes place with oxalic acid diethyl ester in sodium ethylate-ethanol alkaline system then, makes products therefrom experience acidic hydrolysis again;
(3) utilize catalyzer such as acetic acid to make the product condensation that step (1) and step (2) obtain and slough 1 molecular water, make it the saponification in solvent such as THF and ethanol with alkali such as sodium bicarbonate again, obtaining wherein, Q is NH, R
1And R
2General formula (I) compound as defined above.
The compound of general formula I of the present invention or its pharmaceutically useful salt can use separately; or use with the form of pharmaceutical composition with pharmaceutically useful carrier or vehicle; when using with the form of pharmaceutical composition; usually with the compound of Formula I of the present invention of effective dose or its pharmacologically acceptable salt or hydrate and one or more pharmaceutically acceptable carrier or thinner in conjunction with making suitable administration form or dosage form, this program comprises by suitable manner component mixing, granulation, compression or dissolving.Therefore, the invention provides pharmaceutical composition, it comprises compound, its all possible isomer or its pharmacologically acceptable salt or the hydrate and at least a pharmaceutically useful carrier of general formula I.
The pharmaceutical composition of The compounds of this invention can following aspect any-mode grant: in oral, spraying suction, rectal administration, intranasal administration, vagina administration, topical, parenterai administration such as subcutaneous, vein, intramuscular, intraperitoneal, the sheath, in the ventricle, in the breastbone or intracranial injection or input, or by a kind of reservoir medication of outer planting, wherein preferred oral, intramuscular injection, intraperitoneal or intravenously application method.
The compounds of this invention or contain its pharmaceutical composition can the unit dosage form administration.Form of administration can be liquid dosage form, solid dosage.Liquid dosage form can be true solution class, colloidal type, particulate formulations, emulsion dosage form, mixed suspension form.Other formulations are tablet, capsule, dripping pill, aerosol, pill, pulvis, solution, suspensoid, emulsion, granule, suppository, lyophilized injectable powder, inclusion compound, implants, patch, liniment etc. for example.
Can also contain carrier commonly used in the pharmaceutical composition of the present invention, pharmaceutically acceptable carrier described here is including, but not limited to ion-exchanger, aluminum oxide, aluminum stearate, Yelkin TTS, serum protein such as human serum protein, buffer substance such as phosphoric acid salt, glycerine, Sorbic Acid, potassium sorbate, the partial glycerol ester mixture of saturated vegetable fatty acid, water, salt or ionogen, as protamine sulfate, Sodium phosphate dibasic, potassium hydrogen phosphate, sodium-chlor, zinc salt, colloided silica, Magnesium Trisilicate, polyvinylpyrrolidone, cellulosic material, polyoxyethylene glycol, Xylo-Mucine, polyacrylic ester, beeswax, wool grease etc.The content of carrier in pharmaceutical composition can be 1 weight %-98 weight %, accounts for 80 weight % usually greatly.For simplicity, local anesthetic, sanitas, buffer reagents etc. can directly be dissolved in the carrier.
Oral tablet and capsule can contain vehicle such as tackiness agent, as syrup, and gum arabic, sorbyl alcohol, tragacanth, or polyvinylpyrrolidone, weighting agent is as lactose, sucrose, W-Gum, calcium phosphate, sorbyl alcohol, Padil, lubricant, as Magnesium Stearate, talcum, polyoxyethylene glycol, tripoli, disintegrating agent, as yam starch, or acceptable dibutyl phthalate, as bay sodium alkoxide vitriol.Tablet can be with known method dressing on the pharmacopedics.
Oral liquid can be made the suspension of water and oil, solution, and emulsion, syrup or elixir also can be made dry product, with preceding make up water or other suitable medium.This liquid preparation can comprise conventional additive, as suspension agent, and sorbyl alcohol, Walsroder MC 20000S, dextrose syrup, gel, Natvosol, carboxymethyl cellulose, aluminium stearate gel, hydrogenant food oils, emulsifying agent, as Yelkin TTS, sorb gathers candy list oleate, Sudan Gum-arabic; Or nonaqueous carrier (may comprise edible oil), as Prunus amygdalus oil, grease such as glycerine, ethylene glycol, or ethanol; Sanitas is as methyl p-hydroxybenzoate or propyl ester, Sorbic Acid.Can add seasonings or tinting material as needs.
Suppository can comprise conventional suppository base, as cocoa butter or other glyceryl ester.
Stomach is offerd medicine outward, and liquid formulation is made by compound and a kind of disinfectant carrier usually.The first-selected water of carrier.Different according to selected carrier and drug level, compound had both dissolved in and also can be made into aaerosol solution in the carrier, and was earlier that compound is soluble in water when making injection solution, packed into after the filter-sterilized and sealed in bottle or the ampoule.
When topical application, The compounds of this invention can be made suitable ointment, lotion, or the form of creme, and wherein activeconstituents suspends or is dissolved in one or more the carrier.Wherein the operable carrier of ointment formulation is including, but not limited to mineral oil, Albolene, white vaseline, propylene glycol, polyoxyethylene, polyoxytrimethylene, emulsifying wax and water; The spendable carrier of lotion and creme includes but not limited to: mineral oil, and sorbitan monostearate, polysorbate60, the n-Hexadecane ester type waxes, cetene is fragrant and mellow, 2-Standamul G, benzyl alcohol and water.
According to the difference of administering mode, can contain weight ratio 0.1% in the component, or the active ingredient of weight ratio 10-60% more suitably.But when comprising unitary dose in the component, each unit preferably comprises 50-500 milligram activeconstituents.Different according to route of administration and administration frequency, the suitable therapeutic dose that is used to be grown up is 100-3000 milligram every day, as 1500 milligrams of every days.This dosage is corresponding to 1.5-50 milligram/kg/day, and proper dosage is 5-20 milligram/kg/day.
Must recognize, the best dosage of compound of Formula I and be at interval by compound property with such as form, approach and the position of administration and external conditionss such as the specific Mammals decision of being treated, and this best dosage can be determined with routine techniques.Must recognize also simultaneously that the best course of treatment, promptly compound of Formula I is at the nominal dosage of every day in the time, available method well known in the art is determined.
Embodiment
Following specific embodiment is the preferred embodiments of the invention, and it should not be construed as the present invention is constituted any restriction.
Fusing point is measured with SRY-1 type fusing point instrument, and thermometer is not calibrated.Mass spectrum is measured by MicromassZabSpec high resolution mass spectrometer (resolving power 1000) and API 3000 series connection quadrupole mass spectrometers.1H NMR is measured by JNM-ECA-400 SUPERCONDUCTING NMR instrument, operating frequency 400MHz.
Embodiment 1.1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 4-(2,6-two chloro-benzyloxies)-phenyl aldehyde
With 20mmol 2,6-dichloro bromobenzyl and 17mmol p-Hydroxybenzaldehyde are dissolved among the DMF of 14mL, are cooled to 0 ℃, stir down to add 20mmol 60%NaH, continue to stir 0.5h, remove ice bath, stirring at room 0.5h.In reaction solution impouring 140mL frozen water, ethyl acetate extraction, washing, anhydrous MgSO
4Dry.Concentrate, the gained crude product gets white crystals through purification by silica gel column chromatography (petrol ether/ethyl acetate wash-out), and mp 75-77 ℃, yield 93.2%.
1H-NMR(d
6-DMSO)δ：5.35(s，2H，-CH
2O)，5.27(d，2H，J＝8.6Hz，Ar-H)，7.50(m，1H，Ar-H)，7.60(m，2H，Ar-H)，7.90(d，2H，J＝8.6Hz，Ar-H)，9.90(s，1H，-CHO).
Step 2 4-(2,6-two chloro-benzyloxies)-phenylcarbinol
30mmol 4-(2,6-two chloro-benzyloxies)-phenyl aldehyde is dissolved in the methyl alcohol of 45mL, under 28-30 ℃ of condition, slowly drips the 18mmol NaBH of preparation in advance
4, 0.6mL 2N NaOH and water 5.4mL solution altogether, continue to stir 0.5h.Add 6N HCl and be neutralized to pH 4, concentrate, ether extraction, washing, anhydrous sodium sulfate drying.Concentrate, get product, need not promptly can be used for next step reaction by purifying.
Step 3 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
50mmol benzylamine and 50mmol ethyl propenoate are dissolved in the ethanol of 20mL, feed nitrogen, stirring at room 24h.Add 50mmol oxalic acid diethyl ester and alcohol sodium solution (sodium Metal 99.5 52mmol/20mL dehydrated alcohol) then, reflux 1h.Cooling concentrates, and adds 400mL water and 6mL concentrated hydrochloric acid.Filter, the thick product of gained ethanol/water recrystallization gets white crystals, and mp 137-139 ℃, yield 78.5%.
Step 4 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
With 7mmol 4-(2,6-two chloro-benzyloxies)-phenylcarbinol, 7mmol 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester and 7.7mmol triphenyl phosphorus are dissolved among the 30mL THF, be cooled to 0 ℃, drip the 7mmol diethylazodicarboxylate (DEAD) and the 8mL THF solution of preparation in advance, room temperature reaction spends the night.Concentrate, crude product gets white solid, yield 76.6% through purification by silica gel column chromatography (petrol ether/ethyl acetate/methanol-eluted fractions).
1H-NMR(CDCl
3)δ：1.28(t，3H，J＝7.0Hz，-CH
3)，3.86(s，2H，2-CH
2)，4.21(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.62(s，2H，1-NCH
2)，5.27(s，2H，-CH
2O)，5.76(s，2H，-CH
2O)，6.99(d，2H，J＝8.6Hz，Ar-H)，7.20-7.37(m，8H，Ar-H)，7.42(d，2H，J＝8.6Hz，Ar-H).
Step 5 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
With 2mmol 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester is dissolved in the methyl alcohol of 100mL, adds 25mmol1N NaOH solution then, room temperature reaction 3h.In reaction solution impouring 250mL water, ether extraction, water layer is transferred pH 1-2 with concentrated hydrochloric acid, ethyl acetate extraction, washing, anhydrous sodium sulfate drying.Concentrate, the crude product re-crystallizing in ethyl acetate gets white crystals, 162 ℃ of dp, yield 26.4%.
1H-NMR(d
6-DMSO)δ：3.88(s，2H，2-CH
2)，4.57(s，2H，1-NCH
2)，5.23(s，2H，-CH
2O)，5.58(s，2H，-CH
2O)，7.06(d，2H，J＝8.7Hz，Ar-H)，7.20(m，2H，Ar-H)，7.29(m，1H，Ar-H)，7.33(m，2H，Ar-H)，7.37(d，2H，J＝8.7Hz，Ar-H)，7.47(m，1H，Ar-H)，7.56(m，2H，Ar-H)，12.85(s，1H，-COOH).ESI MS(m/z)：496(M
+-1).
Embodiment 2.4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-heptyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with heptyl amice, get white crystals, mp 124-126 ℃, yield 75.8%.
Step 2 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-heptyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2, and 5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets white solid, and mp 89-90 ℃, yield 75.1%.
1H-NMR(CDCl
3)δ：0.86(t，3H，-CH
3)，1.27-1.33(m，11H，-4CH
2CH
3，-OCH
2CH
3)，1.56(m，2H，-CH
2)，3.43(t，2H，1-NCH
2)，3.95(s，2H，2-CH
2)，4.24(q，2H，J＝7.2Hz，-OCH
2CH
3)，5.26(s，2H，-CH
2O)，5.74(s，2H，-CH
2O)，6.98(d，2H，J＝8.6Hz，Ar-H)，7.24(m，1H，Ar-H)，7.35(d，2H，Ar-H)，7.40(d，2H，J＝8.6Hz，Ar-H).
Step 3 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product dehydrated alcohol recrystallization, get white crystals, 125 ℃ of dp, yield 15.3%.
1H-NMR(d
6-DMSO)δ：0.85(t，3H，-CH
3)，1.24(m，8H，-4CH
2)，1.51(m，2H，-CH
2)，3.36(t，2H，1-NCH
2)，3.97(s，2H，2-CH
2)，5.22(s，2H，-CH
2O)，5.56(s，2H，-CH
2O)，7.04(d，2H，J＝8.6Hz，Ar-H)，7.35(d，2H，J＝8.6Hz，Ar-H)，7.47(m，1H，Ar-H)，7.56(m，2H，Ar-H)，12.81(s，1H，-COOH).ESI MS(m/z)：504(M
+-1).
Embodiment 3.4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-octyl group-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with octylame, get white crystals, mp 121-123 ℃, yield 78.3%.
Step 2 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-octyl group-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2, and 5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets white solid, and mp 78-79 ℃, yield 75.8%.
1H-NMR(CDCl
3)δ：0.87(t，3H，-CH
3)，1.26-1.33(m，13H，-5CH
2CH
3，-OCH
2CH
3)，1.56(m，2H，-CH
2)，3.43(t，2H，1-NCH
2)，3.95(s，2H，2-CH
2)，4.24(q，2H，J＝7.0Hz，-OCH
2CH
3)，5.26(s，2H，-CH
2O)，5.74(s，2H，-CH
2O)，6.98(d，2H，J＝8.4Hz，Ar-H)，7.24(m，1H，Ar-H)，7.35(d，2H，Ar-H)，7.40(d，2H，J＝8.4Hz，Ar-H).
Step 3 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product dehydrated alcohol recrystallization, get white crystals, 109 ℃ of dp, yield 12.9%.
1H-NMR(d
6-DMSO)δ：0.84(t，3H，-CH
3)，1.24(m，10H，-5CH
2)，1.51(m，2H，-CH
2)，3.33(t，2H，1-NCH
2)，3.97(s，2H，2-CH
2)，5.22(s，2H，-CH
2O)，5.56(s，2H，-CH
2O)，7.04(d，2H，J＝9.0Hz，Ar-H)，7.35(d，2H，J＝9.0Hz，Ar-H)，7.47(m，1H，Ar-H)，7.55(m，2H，Ar-H)，12.80(s，1H，-COOH).ESI MS(m/z)：518(M
+-1).
Embodiment 4.4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-hexyl-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-hexyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with hexylamine, get white crystals, mp 132-134 ℃, yield 69.3%.
Step 2 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-hexyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-hexyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2, and 5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets white solid, and mp 58-59 ℃, yield 74.2%.
1H-NMR(CDCl
3)δ：0.88(t，3H，-CH
3)，1.29-1.33(m，9H，-3CH
2CH
3，-OCH
2CH
3)，1.56(m，2H，-CH
2)，3.44(t，2H，1-NCH
2)，3.95(s，2H，2-CH
2)，4.24(q，2H，J＝7.0Hz，-OCH
2CH
3)，5.26(s，2H，-CH
2O)，5.74(s，2H，-CH
2O)，6.98(d，2H，J＝8.6Hz，Ar-H)，7.24(m，1H，Ar-H)，7.35(d，2H，Ar-H)，7.40(d，2H，J＝8.6Hz，Ar-H).
Step 3 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-hexyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-hexyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product dehydrated alcohol recrystallization, get white crystals, 136 ℃ of dp, yield 20.4%.
1H-NMR(d
6-DMSO)δ：0.85(t，3H，-CH
3)，1.24(m，6H，-3CH
2)，1.51(m，2H，-CH
2)，3.34(t，2H，1-NCH
2)，3.97(s，2H，2-CH
2)，5.22(s，2H，-CH
2O)，5.56(s，2H，-CH
2O)，7.04(d，2H，J＝8.6Hz，Ar-H)，7.35(d，2H，J＝8.6Hz，Ar-H)，7.47(m，1H，Ar-H)，7.56(m，2H，Ar-H)，12.81(s，1H，-COOH).ESI MS(m/z)：490(M
+-1).
Embodiment 5.4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-furans-2-ylmethyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with furans-2-base-methylamine, get white crystals, mp 132-134 ℃, yield 74.8%.
Step 2 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-furans-2-ylmethyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 87-89 ℃, yield 75.1%.
1H-NMR(CDCl
3)δ：1.30(t，3H，J＝7.0Hz，-CH
3)，3.96(s，2H，2-CH
2)，4.23(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.61(s，2H，1-NCH
2)，5.26(s，2H，-CH
2O)，5.74(s，2H，-CH
2O)，6.28(d，1H，J＝3.0Hz，furan-H)，6.33(dd，1H，J＝3.0Hz，furan-H)，6.99(d，2H，J＝8.6Hz，Ar-H)，7.25(m，1H，Ar-H)，7.35(m，3H，Ar-H，furan-H)，7.41(d，2H，J＝8.6Hz，Ar-H).
Step 3 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate, get white crystals, 146 ℃ of dp, yield 21.2%.
1H-NMR(d
6-DMSO)δ：3.91(s，2H，2-CH
2)，4.58(s，2H，1-NCH
2)，5.23(s，2H，-CH
2O)，5.56(s，2H，-CH
2O)，6.38(d，1H，J＝3.3Hz，furan-H)，6.42(dd，1H，J＝3.3Hz，furan-H)，7.05(d，2H，J＝8.6Hz，Ar-H)，7.37(d，2H，J＝8.6Hz，Ar-H)，7.45(m，1H，Ar-H)，7.56-7.63(m，3H，Ar-H，furan-H)，12.90(s，1H，-COOH).ESIMS(m/z)：486(M
+-1).
Embodiment 6.1-(2-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-(2-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with 2-chloro-benzylamine, get white crystals, mp165-166 ℃, yield 76.0%.
Step 2 1-(2-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-(2-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 99-100.5 ℃, yield 44.7%.
1H-NMR(CDCl
3)δ：1.29(t，3H，J＝7.0Hz，-CH
3)，3.90(s，2H，2-CH
2)，4.22(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.76(s，2H，1-NCH
2)，5.27(s，2H，-CH
2O)，5.76(s，2H，-CH
2O)，6.99(d，2H，J＝8.6Hz，Ar-H)，7.16-7.27(m，4H，Ar-H)，7.36-7.39(d，3H，Ar-H)，7.42(d，2H，J＝8.6Hz，Ar-H).
Step 3 1-(2-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-(2-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product dehydrated alcohol recrystallization, get white crystals, 167 ℃ of dp, yield 23.9%.
1H-NMR(d
6-DMSO)δ：3.71(s，2H，2-CH
2)，4.57(s，2H，1-NCH
2)，5.22(s，2H，-CH
2O)，5.47(s，2H，-CH
2O)，7.06(d，2H，J＝8.6Hz，Ar-H)，7.09(dd，1H，Ar-H)，7.32(dd，2H，Ar-H)，7.35(d，2H，J＝8.6Hz，Ar-H)，7.45-7.49(m，2H，Ar-H)，7.56(m，2H，Ar-H).ESIMS(m/z)：530(M
+-1).
Embodiment 7.1-(3-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-(3-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with 3-chloro-benzylamine, get white crystals, mp134-135 ℃, yield 79.2%.
Step 2 1-(3-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-(3-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 130-131 ℃, yield 52.9%.
1H-NMR(CDCl
3)δ：1.29(t，3H，J＝7.0Hz，-CH
3)，3.87(s，2H，2-CH
2)，4.22(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.59(s，2H，1-NCH
2)，5.27(s，2H，-CH
2O)，5.76(s，2H，-CH
2O)，7.00(d，2H，J＝8.7Hz，Ar-H)，7.09(m，1H，Ar-H)，7.21-7.28(m，4H，Ar-H)，7.36(d，2H，Ar-H)，7.42(d，2H，J＝8.7Hz，Ar-H).
Step 3 1-(3-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-(3-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product dehydrated alcohol recrystallization, get white crystals, 148 ℃ of dp, yield 16.4%.
1H-NMR(d
6-DMSO)δ：3.71(s，2H，2-CH
2)，4.57(s，2H，1-NCH
2)，5.22(s，2H，-CH
2O)，5.47(s，2H，-CH
2O)，7.02(d，2H，J＝8.7Hz，Ar-H)，7.09(dd，1H，Ar-H)，7.32(dd，2H，Ar-H)，7.35(d，2H，J＝8.7Hz，Ar-H)，7.45-7.49(m，2H，Ar-H)，7.56(m，2H，Ar-H).ESIMS(m/z)：530(M
+-1).
Embodiment 8.1-(3-trifluoromethyl-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-(3-trifluoromethyl-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with 3-trifluoromethyl-benzylamine, get white crystals, mp 156-158 ℃, yield 78.2%.
Step 2 1-(3-trifluoromethyl-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-(3-trifluoromethyl-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 117-119 ℃, yield 41.9%.
1H-NMR(CDCl
3)δ：1.27(t，3H，J＝7.2Hz，-CH
3)，3.88(s，2H，2-CH
2)，4.22(q，2H，J＝7.2Hz，-OCH
2CH
3)，4.67(s，2H，1-NCH
2)，5.27(s，2H，-CH
2O)，5.76(s，2H，-CH
2O)，7.00(d，2H，J＝8.6Hz，Ar-H)，7.23(m，1H，Ar-H)，7.36-7.49(m，7H，Ar-H)，7.56(d，1H，Ar-H).
Step 3 1-(3-trifluoromethyl-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-(3-trifluoromethyl-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate, get white crystals, 163 ℃ of dp, yield 11.4%.
1H-NMR(d
6-DMSO)δ：3.95(s，2H，2-CH
2)，4.67(s，2H，1-NCH
2)，5.23(s，2H，-CH
2O)，5.58(s，2H，-CH
2O)，7.05(d，2H，J＝8.6Hz，Ar-H)，7.37(d，2H，J＝8.6Hz，Ar-H)，7.46-7.68(m，7H，Ar-H)，12.89(s，1H，-COOH).ESI MS(m/z)：564(M
+-1).
Embodiment 9.1-(4-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-(4-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with 4-chloro-benzylamine, get white crystals, mp164-167 ℃, yield 75.5%.
Step 2 1-(4-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-(4-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 91-93 ℃, yield 39.1%.
1H-NMR(CDCl
3)δ：1.27(t，3H，J＝7.1Hz，-CH
3)，3.85(s，2H，2-CH
2)，4.21(q，2H，J＝7.1Hz，-OCH
2CH
3)，4.58(s，2H，1-NCH
2)，5.27(s，2H，-CH
2O)，5.75(s，2H，-CH
2O)，7.00(d，2H，J＝8.4Hz，Ar-H)，7.14(d，2H，J＝8.4Hz，Ar-H)，7.25(m，1H，Ar-H)，7.30(d，2H，J＝8.4Hz，Ar-H)，7.36(m，2H，Ar-H)，7.41(d，2H，J＝8.4Hz，Ar-H).
Step 3 1-(4-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-(4-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate, get white crystals, 173 ℃ of dp, yield 21.0%.
1H-NMR(d
6-DMSO)δ：3.90(s，2H，2-CH
2)，4.56(s，2H，1-NCH
2)，5.23(s，2H，-CH
2O)，5.58(s，2H，-CH
2O)，7.06(d，2H，J＝8.6Hz，Ar-H)，7.23(d，2H，J＝8.4Hz，Ar-H)，7.37(d，2H，J＝8.6Hz，Ar-H)，7.40(d，2H，J＝8.4Hz，Ar-H)，7.46(m，1H，Ar-H)，7.56(m，2H，Ar-H).ESI MS(m/z)：530(M
+-1).
Embodiment 10.1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-cyclohexyl methyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, substitute benzylamine with cyclohexyl-methylamine, get white crystals, mp174-177 ℃, yield 80.8%.
Step 2 1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-cyclohexyl methyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 118-120 ℃, yield 80.8%.
1H-NMR(CDCl
3)δ：0.95(m，2H，Cyclohexane-H)，1.17(m，3H，Cyclohexane-H)，1.31(t，3H，J＝7.2Hz，-CH
3)，1.58-1.74(m，6H，Cyclohexane-H)，3.26(d，2H，1-NCH
2)，3.96(s，2H，2-CH
2)，4.24(q，2H，J＝7.2Hz，-OCH
2CH
3)，5.26(s，2H，-CH
2O)，5.74(s，2H，-CH
2O)，6.98(d，2H，J＝8.6Hz，Ar-H)，7.22(m，1H，Ar-H)，7.35(d，2H，Ar-H)，7.40(d，2H，J＝8.6Hz，Ar-H).
Step 3 1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product dehydrated alcohol recrystallization, get white crystals, 148 ℃ of dp, yield 11.9%.
1H-NMR(d
6-DMSO)δ：0.88(m，2H，Cyclohexane-H)，1.16(m，3H，Cyclo-hexane-H)，1.54(m，6H，Cyclohexane-H)，3.18(d，2H，1-NCH
2)，3.97(s，2H，2-CH
2)，5.22(s，2H，-CH
2O)，5.55(s，2H，-CH
2O)，7.04(d，2H，J＝8.6Hz，Ar-H)，7.35(d，2H，J＝8.6Hz，Ar-H)，7.45(m，1H，Ar-H)，7.55(m，2H，Ar-H)，12.78(s，1H，-COOH).ESIMS(m/z)：502(M
+-1).
Embodiment 11.1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-benzo [1,3] dioxolane-5-ylmethyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 3, with benzo [1,3] dioxolane-5-base-methylamine substitutes benzylamine, white crystals, mp 146-148 ℃, yield 78.1%.
Step 2 1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 1-benzo [1,3] dioxolane-5-ylmethyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2, and 5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets white solid, mp 112-115 ℃, yield 86.1%.
1H-NMR(CDCl
3)δ：1.27(t，3H，J＝7.0Hz，-CH
3)，3.84(s，2H，2-CH
2)，4.21(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.52(s，2H，1-NCH
2)，5.27(s，2H，-CH
2O)，5.75(s，2H，-CH
2O)，5.95(s，2H，-OCH
2O-)，6.68-6.77(m，3H，Ar-H)，6.99(d，2H，J＝8.7Hz，Ar-H)，7.25(m，1H，Ar-H)，7.36(d，2H，Ar-H)，7.36(d，2H，Ar-H)，7.42(d，2H，J＝8.7Hz，Ar-H).
Step 3 1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate gets white crystals, 163 ℃ of dp, yield 14.2%.
1H-NMR(d
6-DMSO)δ：3.86(s，2H，2-CH
2)，4.46(s，2H，1-NCH
2)，5.23(s，2H，-CH
2O)，5.57(s，2H，-CH
2O)，5.99(s，2H，-OCH
2O-)，6.70-6.88(m，3H，Ar-H)，7.05(d，2H，J＝8.6Hz，Ar-H)，7.37(d，2H，J＝8.6Hz，Ar-H)，7.45(m，1H，Ar-H)，7.55(m，2H，Ar-H)，12.81(s，1H，-COOH).ESI MS(m/z)：540(M
+-1).
Embodiment 12.1-benzyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 4-(3,5-two fluoro-benzyloxies)-phenyl aldehyde
With 24mmol 3,5-difluoro bromobenzyl and 20mmol p-Hydroxybenzaldehyde are dissolved among the DMF of 16mL, are cooled to 0 ℃, stir down to add 24mmol 60%NaH, continue to stir 0.5h, remove ice bath, stirring at room 0.5h.In reaction solution impouring 170mL frozen water, ethyl acetate extraction, washing, anhydrous MgSO
4Dry.Concentrate, get product, need not promptly can be used for next step reaction by purifying.
Step 2 4-(3,5-two fluoro-benzyloxies)-phenylcarbinol
20mmol 4-(3,5-two fluoro-benzyloxies)-phenyl aldehyde is dissolved in the methyl alcohol of 30mL, under 28-30 ℃ of condition, slowly drips the 12mmol NaBH of preparation in advance
4, 0.4mL 2N NaOH and water 3.6mL solution altogether, continue to stir 0.5h.Add 6N HCl and be neutralized to pH 4, concentrated, add 100mL water, stir 4h, filter, washing, drying gets white crystals, yield 85.8%.
Step 3 1-benzyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, substitute 4-(2,6-two chloro-benzyloxies)-phenylcarbinol with 4-(3,5-two fluoro-benzyloxies)-phenylcarbinol, get white solid, mp 108-110 ℃, yield 40.8%.
1H-NMR(CDCl
3)δ：1.27(t，3H，J＝7.0Hz，-CH
3)，3.86(s，2H，2-CH
2)，4.20(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.61(s，2H，1-NCH
2)，5.04(s，2H，-CH
2O)，5.74(s，2H，-CH
2O)，6.73(m，1H，Ar-H)，6.91(d，2H，J＝8.6Hz，Ar-H)，6.96(m，2H，Ar-H)，7.20-7.36(m，5H，Ar-H)，7.40(d，2H，J＝8.6Hz，Ar-H).
Step 4 1-benzyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-benzyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate, get white crystals, 157 ℃ of dp, yield 20%.
1H-NMR(d
6-DMSO)δ：3.87(s，2H，2-CH
2)，4.56(s，2H，1-NCH
2)，5.15(s，2H，-CH
2O)，5.56(s，2H，-CH
2O)，7.01(d，2H，J＝8.9Hz，Ar-H)，7.17-7.37(m，10H，Ar-H)，12.83(s，1H，-COOH).ESI MS(m/z)：464(M
+-1).
Embodiment 13.1-(3-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-(3-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2 of phenylcarbinol, 6-two chloro-benzyloxies)-and phenylcarbinol, with 1-(3-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 94-95 ℃, yield 77.0%.
1H-NMR(CDCl
3)δ：1.28(t，3H，J＝7.2Hz，-CH
3)，3.87(s，2H，2-CH
2)，4.21(q，2H，J＝7.2Hz，-OCH
2CH
3)，4.58(s，2H，1-NCH
2)，5.04(s，2H，-CH
2O)，5.73(s，2H，-CH
2O)，6.73(m，1H，Ar-H)，6.92(d，2H，J＝8.6Hz，Ar-H)，6.96(m，2H，Ar-H)，7.09(m，1H，Ar-H)，7.20-7.28(m，3H，Ar-H)，7.40(d，2H，J＝8.6Hz，Ar-H).
Step 2 1-benzyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-(3-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate, get white crystals, 146 ℃ of dp, yield 16.9%.
1H-NMR(d
6-DMSO)δ：3.92(s，2H，2-CH
2)，4.57(s，2H，1-NCH
2)，5.15(s，2H，-CH
2O)，5.55(s，2H，-CH
2O)，7.01(d，2H，J＝8.7Hz，Ar-H)，7.17-7.38(m，9H，Ar-H)，12.75(s，1H，-COOH).ESI MS(m/z)：498(M
+-1).
Embodiment 14.1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2,6-two chloro-benzyloxies) of phenylcarbinol-phenylcarbinol, with 1-benzo [1,3] dioxolane-5-ylmethyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2, and 5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets white solid, mp 99-100.5 ℃, yield 69.8%.
1H-NMR(CDCl
3)δ：1.27(t，3H，J＝7.0Hz，-CH
3)，3.84(s，2H，2-CH
2)，4.20(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.51(s，2H，1-NCH
2)，5.04(s，2H，-CH
2O)，5.73(s，2H，-CH
2O)，5.94(s，2H，-OCH
2O-)，6.68-6.76(m，4H，Ar-H)，6.91(d，2H，J＝8.6Hz，Ar-H)，6.96(m，2H，Ar-H)，7.39(d，2H，J＝8.6Hz，Ar-H).
Step 2 1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate gets white crystals, 172 ℃ of dp, yield 18.9%.
1H-NMR(d
6-DMSO)δ：3.85(s，2H，2-CH
2)，4.45(s，2H，1-NCH
2)，5.15(s，2H，-CH
2O)，5.55(s，2H，-CH
2O)，6.00(s，2H，-OCH
2O-)，6.71(dd，1H，Ar-H)，6.80(d，1H，Ar-H)，6.86(d，1H，Ar-H)，7.00(d，2H，J＝8.6Hz，Ar-H)，7.19(m，3H，Ar-H)，7.35(d，2H，J＝8.6Hz，Ar-H)，12.82(s，1H，-COOH).ESI MS(m/z)：508(M
+-1).
Embodiment 15.4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2 of phenylcarbinol, 6-two chloro-benzyloxies)-and phenylcarbinol, with 1-heptyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 75-77 ℃, yield 69%.
1H-NMR(CDCl
3)δ：0.86(t，3H，-CH
3)，1.27-1.32(m，11H，-4CH
2CH
3，-OCH
2CH
3)，1.57(m，2H，-CH
2)，3.43(t，2H，1-NCH
2)，3.95(s，2H，2-CH
2)，4.24(q，2H，J＝7.0Hz，-OCH
2CH
3)，5.03(s，2H，-CH
2O)，5.71(s，2H，-CH
2O)，6.72(m，1H，Ar-H)，6.90(d，2H，J＝8.6Hz，Ar-H)，6.96(m，4H，Ar-H)，7.38(d，2H，J＝8.6Hz，Ar-H).
Step 2 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product dehydrated alcohol recrystallization, get white crystals, 122 ℃ of dp, yield 14.7%.
1H-NMR(d
6-DMSO)δ：0.85(t，3H，-CH
3)，1.24(m，8H，-4CH
2)，1.50(m，2H，-CH
2)，3.34(t，2H，1-NCH
2)，3.96(s，2H，2-CH
2)，5.14(s，2H，-CH
2O)，5.53(s，2H，-CH
2O)，6.99(d，2H，J＝8.6Hz，Ar-H)，7.16-7.22(m，3H，Ar-H)，7.33(d，2H，J＝8.6Hz，Ar-H)，12.80(s，1H，-COOH).ESI MS(m/z)：472(M
+-1).
Embodiment 16.1-(2-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-(2-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2 of phenylcarbinol, 6-two chloro-benzyloxies)-and phenylcarbinol, with 1-(2-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 88-90 ℃, yield 71.6%.
1H-NMR(CDCl
3)δ：1.29(t，3H，J＝7.0Hz，-CH
3)，3.90(s，2H，2-CH
2)，4.21(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.76(s，2H，1-NCH
2)，5.04(s，2H，-CH
2O)，5.73(s，2H，-CH
2O)，6.73(m，1H，Ar-H)，6.91(d，2H，J＝8.6Hz，Ar-H)，6.96(m，2H，Ar-H)，7.18-7.27(m，3H，Ar-H)，7.37(m，1H，Ar-H)，7.42(d，2H，J＝8.6Hz，Ar-H).
Step 2 1-(2-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-(2-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate, get white crystals, 167 ℃ of dp, yield 24.2%.
1H-NMR(d
6-DMSO)δ：3.90(s，2H，2-CH
2)，4.66(s，2H，1-NCH
2)，5.15(s，2H，-CH
2O)，5.56(s，2H，-CH
2O)，7.01(d，2H，J＝8.6Hz，Ar-H)，7.17-7.50(m，9H，Ar-H)，12.87(s，1H，-COOH).ESI MS(m/z)：498(M
+-1).
Embodiment 17.1-cyclohexyl methyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-cyclohexyl methyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2 of phenylcarbinol, 6-two chloro-benzyloxies)-and phenylcarbinol, with 1-cyclohexyl methyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 106-108 ℃, yield 82.2%.
Step 2 1-cyclohexyl methyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-cyclohexyl methyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product anhydrous diethyl ether recrystallization, get white crystals, 150 ℃ of dp, yield 21.6%.
1H-NMR(d
6-DMSO)δ：0.88(m，2H，Cyclohexane-H)，1.15(m，3H，Cyclo-hexane-H)，1.54(m，6H，Cyclohexane-H)，3.18(d，2H，1-NCH
2)，3.96(s，2H，2-CH
2)，5.14(s，2H，-CH
2O)，5.53(s，2H，-CH
2O)，6.99(d，2H，J＝8.6Hz，Ar-H)，7.16(m，3H，Ar-H)，7.33(d，2H，J＝8.6Hz，Ar-H)，12.79(s，1H，-COOH).ESI MS(m/z)：470(M
+-1).
Embodiment 18.4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2 of phenylcarbinol, 6-two chloro-benzyloxies)-and phenylcarbinol, with 1-octyl group-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 70-72 ℃, yield 71.7%.
1H-NMR(CDCl
3)δ：0.87(t，3H，-CH
3)，1.26-1.32(m，13H，-5CH
2CH
3，-OCH
2CH
3)，1.55(m，2H，-CH
2)，3.43(t，2H，1-NCH
2)，3.95(s，2H，2-CH
2)，4.24(q，2H，J＝7.0Hz，-OCH
2CH
3)，5.03(s，2H，-CH
2O)，5.71(s，2H，-CH
2O)，6.75(m，1H，Ar-H)，6.90(d，2H，J＝8.6Hz，Ar-H)，6.94(m，2H，Ar-H)，7.38(d，2H，J＝8.6Hz，Ar-H).
Step 2 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product dehydrated alcohol recrystallization, get white crystals, 116 ℃ of dp, yield 11.4%.
1H-NMR(d
6-DMSO)δ：0.84(t，3H，-CH
3)，1.18(m，10H，-5CH
2)，1.50(m，2H，-CH
2)，3.33(t，2H，1-NCH
2)，3.96(s，2H，2-CH
2)，5.14(s，2H，-CH
2O)，5.53(s，2H，-CH
2O)，6.99(d，2H，J＝8.7Hz，Ar-H)，7.18(m，3H，Ar-H)，7.33(d，2H，J＝8.7Hz，Ar-H)，12.80(s，1H，-COOH).ESIMS(m/z)：586(M
+-1).
Embodiment 19.1-(3-trifluoromethyl-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-(3-trifluoromethyl-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2,6-two chloro-benzyloxies) of phenylcarbinol-phenylcarbinol, with 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2, and 5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets white solid, mp 114-116 ℃, yield 74.9%.
1H-NMR(CDCl
3)δ：1.26(t，3H，J＝7.2Hz，-CH
3)，3.88(s，2H，2-CH
2)，4.21(q，2H，J＝7.2Hz，-OCH
2CH
3)，4.67(s，2H，1-NCH
2)，5.04(s，2H，-CH
2O)，5.74(s，2H，-CH
2O)，6.73(m，1H，Ar-H)，6.91(d，2H，J＝8.7Hz，Ar-H)，6.95(m，2H，Ar-H)，7.40(d，2H，J＝8.7Hz，Ar-H)，7.45-7.57(m，4H，Ar-H).
Step 2 1-(3-trifluoromethyl-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-(3-trifluoromethyl-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product anhydrous diethyl ether recrystallization, get white crystals, 147 ℃ of dp, yield 16.3%.
1H-NMR(d
6-DMSO)δ：3.94(s，2H，2-CH
2)，4.66(s，2H，1-NCH
2)，5.15(s，2H，-CH
2O)，5.55(s，2H，-CH
2O)，7.00(d，2H，J＝8.4Hz，Ar-H)，7.17(m，3H，Ar-H)，7.35(d，2H，J＝8.4Hz，Ar-H)，7.51-7.68(m，4H，Ar-H)，12.85(s，1H，-COOH).ESI MS(m/z)：532(M
+-1).
Embodiment 20.4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2 of phenylcarbinol, 6-two chloro-benzyloxies)-and phenylcarbinol, with 1-furans-2-ylmethyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 98-100 ℃, yield 94.0%.
Step 2 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, crude product anhydrous diethyl ether recrystallization, get white crystals, 134 ℃ of dp, yield 16.7%.
1H-NMR(d
6-DMSO)δ：3.90(s，2H，2-CH
2)，4.57(s，2H，1-NCH
2)，5.14(s，2H，-CH
2O)，5.53(s，2H，-CH
2O)，6.38(m，2H，furan-H)，7.00(d，2H，J＝8.6Hz，Ar-H)，7.17(m，3H，Ar-H)，7.34(d，2H，J＝8.6Hz，Ar-H)，7.62(m，1H，furan-H)，12.87(s，1H，-COOH).ESIMS(m/z)：454(M
+-1).
Embodiment 21.1-(4-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-(4-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 1 step 4, with 4-(3,5-two fluoro-benzyloxies)-the alternative 4-(2 of phenylcarbinol, 6-two chloro-benzyloxies)-and phenylcarbinol, with 1-(4-chloro-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 115-116 ℃, yield 63.0%.
1H-NMR(CDCl
3)δ：1.27(t，3H，J＝7.0Hz，-CH
3)，3.85(s，2H，2-CH
2)，4.21(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.58(s，2H，1-NCH
2)，5.04(s，2H，-CH
2O)，5.72(s，2H，-CH
2O)，6.73(m，1H，Ar-H)，6.91(d，2H，J＝8.6Hz，Ar-H)，6.95(m，2H，Ar-H)，7.14(d，2H，J＝8.4Hz，Ar-H)，7.29(d，2H，J＝8.6Hz，Ar-H)，7.39(d，2H，J＝8.4Hz，Ar-H).
Step 2 1-(4-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 1 step 5, with 1-(4-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, the crude product re-crystallizing in ethyl acetate, get white crystals, 171 ℃ of dp, yield 18.2%.
1H-NMR(d
6-DMSO)δ：3.89(s，2H，2-CH
2)，4.55(s，2H，1-NCH
2)，5.15(s，2H，-CH
2O)，5.55(s，2H，-CH
2O)，7.01(d，2H，J＝8.6Hz，Ar-H)，7.17(m，3H，Ar-H)，7.23(d，2H，J＝8.6Hz，Ar-H)，7.35(d，2H，J＝8.6Hz，Ar-H)，7.39(d，2H，J＝8.6Hz，Ar-H)，12.84(s，1H，-COOH).ESI MS(m/z)：498(M
+-1).
Embodiment 22.1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 11,3-two chloro-2-(4-nitro-Phenoxymethyl)-benzene
With 10mmol 2,6-dichloro bromobenzyl and 10mmol p-NP join in the alcohol sodium solution (sodium Metal 99.5 10mmol/10mL dehydrated alcohol), reflux 2h, and cooling concentrates.Add water 20mL, filter, washing gets faint yellow solid 2.8g, yield 96.5%.
Step 2 4-(2,6-two chloro-benzyloxies)-aniline
With 6.7mmol 1,3-two chloro-2-(4-nitro-Phenoxymethyl)-benzene and 33.6mmol tin protochloride are dissolved in the 67mL ethanol, stir reflux 5h.Cooling is evaporated to driedly, adds the 80mL ethyl acetate in resistates, uses NaHCO
3Transfer pH value of solution 7-8, leach insolubles, with ethyl acetate repetitive scrubbing filter residue, merging filtrate, washing, anhydrous Na
2SO
4Dry.Concentrate, get faint yellow oily thing, need not can carry out next step reaction by purifying.
Step 3 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
With 7.2mmol 4-(2,6-two chloro-benzyloxies)-aniline and 7.2mmol 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester (embodiment 1 step 3 product) is dissolved in the 10mL Glacial acetic acid, stirs reflux 4h.Cooling carefully splashes into NaHCO with reaction solution
3In the saturated aqueous solution, ethyl acetate extraction, washing, anhydrous Na
2SO
4Dry.Concentrate, the gained crude product gets faint yellow solid through purification by silica gel column chromatography, and mp 105-107 ℃, yield 58.6%.
1H-NMR(CDCl
3)δ：0.99(t，3H，J＝7.0Hz，-CH
3)，3.95(m，4H，2-CH
2，-OCH
2CH
3)，4.62(s，2H，1-NCH
2)，5.19(s，2H，-CH
2O)，6.93(d，2H，J＝8.9Hz，Ar-H)，7.01(d，2H，J＝8.9Hz，Ar-H)，7.26-7.39(m，5H，Ar-H)，7.45(m，1H，Ar-H)，7.55(m，2H，Ar-H)，8.63(s，1H，-NH).
Step 4 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
With 4mmol 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester is dissolved in 51mL tetrahydrofuran (THF) and the 17mL ethanol, stirs down, adds 20mmol 5%Na HCO
3The aqueous solution, reflux 48h.Cooling in reaction solution impouring 200mL water, is transferred pH1-2 with 2N hydrochloric acid, ethyl acetate extraction, washing, anhydrous Na
2SO
4Dry.Concentrate, gained crude product re-crystallizing in ethyl acetate gets the off-white color solid, 155 ℃ of dp, yield 63.4%.
1H-NMR(d
6-DMSO)δ：3.93(s，2H，2-CH
2)，4.60(s，2H，1-NCH
2)，5.18(s，2H，-CH
2O)，6.92(d，2H，J＝8.9Hz，Ar-H)，7.03(d，2H，J＝8.9Hz，Ar-H)，7.25-7.38(m，5H，Ar-H)，7.45(m，1H，Ar-H)，7.56(m，2H，Ar-H)，8.55(s，1H，-NH)，12.35(s，1H，-COOH).ESI MS(m/z)：481(M
+-1).
Embodiment 23. 4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-1-(3-trifluoromethyl-benzyl)-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-1-(3-trifluoromethyl-benzyl)-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to embodiment 22 steps 3, with 1-(3-trifluoromethyl-benzyl)-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester (embodiment 8 step 1 products) substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp71-73 ℃, yield 53.4%.
1H-NMR(CDCl
3)δ：1.21(t，3H，J＝7.0Hz，-CH
3)，3.95(s，2H，2-CH
2)，4.16(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.69(s，2H，1-NCH
2)，5.25(s，2H，-CH
2O)，6.97(d，2H，J＝8.9Hz，Ar-H)，7.11(d，2H，J＝8.9Hz，Ar-H)，7.22(m，1H，Ar-H)，7.35(d，2H，Ar-H)，7.46-7.57(m，4H，Ar-H)，8.16(s，1H，-NH).
Step 2 4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-1-(3-trifluoromethyl-benzyl)-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to embodiment 22 steps 4, with 4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-1-(3-trifluoromethyl-benzyl)-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets yellow crystal, 170 ℃ of dp, yield 25.3%.
1H-NMR(d
6-DMSO)δ：3.99(s，2H，2-CH
2)，4.70(s，2H，1-NCH
2)，5.18(s，2H，-CH
2O)，6.92(d，2H，J＝8.9Hz，Ar-H)，7.07(d，2H，J＝8.9Hz，Ar-H)，7.44-7.68(m，7H，Ar-H)，8.53(s，1H，-NH)，12.35(s，1H，-COOH).ESI MS(m/z)：549(M
+-1).
Embodiment 24. 1-benzo [1,3] dioxolane-5-base-methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-benzo [1,3] dioxolane-5-base-methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to implementing sharp 22 steps 3, with 1-benzo [1,3] dioxolane-5-base-methyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester (embodiment 14 step 1 products) substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get yellow solid, mp 101-103 ℃, yield 59.6%.
1H-NMR(CDCl
3)δ：1.20(t，3H，J＝7.0Hz，-CH
3)，3.93(s，2H，2-CH
2)，4.15(q，2H，J＝7.0Hz，-OCH
2CH
3)，4.54(s，2H，1-NCH
2)，5.26(s，2H，-CH
2O)，5.95(s，2H，-OCH
2O-)，6.75(m，3H，Ar-H)，6.97(d，2H，J＝8.9Hz，Ar-H)，7.11(d，2H，J＝8.9Hz，Ar-H)，7.23(m，1H，Ar-H)，7.36(d，2H，Ar-H)，8.12(s，1H，-NH).
Step 2 1-benzo [1,3] dioxolane-5-base-methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to implementing sharp 22 steps 4, with 1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get yellow solid, 168 ℃ of dp, yield 57.4%.
1H-NMR(d
6-DMSO)δ：3.91(s，2H，2-CH
2)，4.48(s，2H，1-NCH
2)，5.18(s，2H，-CH
2O)，6.00(s，2H，-OCH
2O-)，6.74-6.89(m，3H，Ar-H)，6.92(d，2H，J＝8.9Hz，Ar-H)，7.37(d，2H，J＝8.9Hz，Ar-H)，7.44(m，1H，Ar-H)，7.55(m，2H，Ar-H)，8.50(s，1H，-NH)，12.35(s，1H，-COOH).ESI MS(m/z)：525(M
+-1).
Embodiment 25.1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to implementing sharp 22 steps 3,1-cyclohexyl methyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester (embodiment 10 step 1 products) substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get white solid, mp 157-159 ℃, yield 46.6%.
1H-NMR(CDCl
3)δ：0.94(m，2H，Cyclohexane-H)，1.17(m，6H，-CH
3，Cyclohexane-H)，1.64(m，6H，Cyclohexane-H)，3.29(d，2H，1-NCH
2)，4.05(s，2H，2-CH
2)，4.14(q，2H，J＝7.0Hz，-OCH
2CH
3)，5.24(s，2H，-CH
2O)，6.94(d，2H，J＝8.9Hz，Ar-H)，7.08(d，2H，J＝8.9Hz，Ar-H)，7.22(m，1H，Ar-H)，7.35(d，2H，Ar-H)，8.02(s，1H，-NH).
Step 2 1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to implementing sharp 22 steps 4, with 1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets yellow solid, 189 ℃ of dp, yield 48.8%.
1H-NMR(d
6-DMSO)δ：0.88(m，2H，Cyclohexane-H)，1.16(m，3H，Cyclo-hexane-H)，1.60(m，6H，Cyclohexane-H)，3.22(d，2H，1-NCH
2)，4.02(s，2H，2-CH
2)，5.16(s，2H，-CH
2O)，6.90(d，2H，J＝8.9Hz，Ar-H)，6.99(d，2H，J＝8.9Hz，Ar-H)，7.44(m，1H，Ar-H)，7.55(m，2H，Ar-H)，8.45(s，1H，-NH)，12.32(s，1H，-COOH).ESI MS(m/z)：487(M
+-1).
Embodiment 26.4-[4-(2,6-two chloro-benzyloxies)-aniline]-1-octyl group-5-oxo-2, the preparation of 5-dihydro-1H-pyrroles-3-carboxylic acid
Step 1 4-[4-(2,6-two chloro-benzyloxies)-aniline]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester
According to implementing sharp 22 steps 3, with 4-(2,6-two chloro-benzyloxies)-aniline and 1-octyl group-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester (embodiment 3 step 1 products) substitutes 1-benzyl-4-hydroxyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester, get the off-white color solid, mp 68-70 ℃, yield 47.5%.
1H-NMR(CDCl
3)δ：0.85(t，3H，-CH
3)，1.19-1.29(m，13H，-5CH
2CH
3，-OCH
2CH
3)，1.57(m，2H，-CH
2)，3.44(t，2H，1-NCH
2)，4.03(s，2H，2-CH
2)，4.15(q，2H，J＝7.2Hz，-OCH
2CH
3)，5.24(s，2H，-CH
2O)，6.94(d，2H，J＝8.9Hz，Ar-H)，7.08(d，2H，J＝8.9Hz，Ar-H)，7.26(m，1H，Ar-H)，7.35(d，2H，Ar-H)，8.01(s，1H，-NH).
Step 2 4-[4-(2,6-two chloro-benzyloxies)-aniline]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid
According to implementing sharp 22 steps 4, with 4-[4-(2,6-two chloro-benzyloxies)-aniline]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester substitutes 1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid, ethyl ester gets faint yellow solid, 146 ℃ of dp, yield 52.8%.
1H-NMR(d
6-DMSO)δ：0.83(t，3H，-CH
3)，1.25(m，10H，-5CH
2)，1.54(m，2H，-CH
2)，3.35(t，2H，1-NCH
2)，4.02(s，2H，2-CH
2)，5.18(s，2H，-CH
2O)，6.90(d，2H，J＝8.9Hz，Ar-H)，6.99(d，2H，J＝8.9Hz，Ar-H)，7.44(m，1H，Ar-H)，7.55(d，2H，Ar-H)，8.45(s，1H，Ar-H)，12.33(s，1H，-COOH).ESI MS(m/z)：503(M
+-1).
The biological activity of The compounds of this invention can be estimated with the following method:
Embodiment 27
The withered grass mycobacterium is gone down to posterity on 125 white horse with a black mane Wen egg slant mediums, cultivated 4-5 days.Get a little inoculation in liquid nutrient medium (contain 0.5% peptone, 0.3% extractum carnis, 2.0% glycerine, the pH value is 7.0-7.2), in 37 ℃, 220rpm jolts 24h, measures the optical density value (OD of 600nm wavelength on enzyme connection instrument
600nm), to OD
600nmBe 0.5-0.6.Inoculate 1.0% bacterium liquid and (contain 0.5% peptone in the calibrating substratum, 0.3% yeast extract paste, 1.2% agar, the pH value is 7.0-7.4) in, pave plate, after treating that flat board solidifies, add the tablet that diameter is 0.7cm in spacing distance greater than 3.0cm, tablet contain concentration be 0.5mM treat SCREENED COMPOUND 100 μ L, simultaneously, if 0.5mM positive compound 1-(6-chloro-3, the 4-methylenedioxy benzyl)-2-carboxyl-5-(2, the 6-dichloro-benzyloxy) indoles (Daines RA, Pendrak I, Sham K, et al.First X-ray cocrystal ctructure of a bacterial FabH condensingenzyme and a small molecule inhibitor achieved using rationaldesign and homology modeling [J] .J Med Chem, 2003,46:58.), 0.1mM vazadrine and blank solvent DMSO contrast.Behind 37 ℃ of cultivation 48h, observe inhibition zone, measure each compound antibacterial circle diameter, ask average test-results 5 times.Test-results is listed in table 1.
Table 1 compound is to the restraining effect of Mycobacterium phlei
| Compound | Average diameter of inhibition zone (cm) | Compound | Average diameter of inhibition zone (cm) |
| Positive compound | 2.2 | Positive compound | 2.2 |
| The vazadrine | 2.3 | The vazadrine | 2.3 |
| Embodiment 1 | 0.6 | Embodiment 14 | 0.9 |
| Embodiment 2 | 1.7 | Embodiment 15 | 0.5 |
| Embodiment 3 | 2.0 | Embodiment 16 | 0.8 |
| Embodiment 4 | 1.5 | Embodiment 17 | 0.8 |
| Embodiment 5 | 1.3 | Embodiment 18 | 0.7 |
| Embodiment 6 | 1.6 | Embodiment 19 | 0.6 |
| Embodiment 7 | 1.8 | Embodiment 20 | 0.6 |
| Embodiment 8 | 2.0 | Embodiment 21 | 0.7 |
| Embodiment 9 | 1.7 | Embodiment 22 | 1.8 |
| Embodiment 10 | 1.7 | Embodiment 23 | 2.0 |
| Embodiment 11 | 1.3 | Embodiment 24 | 2.1 |
| Embodiment 12 | 0.8 | Embodiment 25 | 0.8 |
| Embodiment 13 | 1.6 | Embodiment 26 | 1.4 |
Claims (7)
1. the compound of general formula I, its all possible isomer or its pharmaceutically useful salt or hydrate:
Wherein:
Q is CH
2O or NH;
R
1Be aryl;
R
2Be aryl, C
3-10Alkyl or C
4-8Cycloalkyl.
Wherein " aryl " is meant phenyl, or by hydroxyl, halogen, nitro, CF
3, methylene-dioxy, C
1-6Alkyl, C
1-6Alkoxy substituent one or polysubstituted phenyl.
2. the compound of claim 1, it is selected from:
1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-hexyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(2-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(3-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(3-trifluoromethyl-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(4-chloro-benzyl)-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(2,6-two chloro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-benzyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(3-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-benzo [1,3] dioxolane-5-ylmethyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-heptyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(2-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-cyclohexyl methyl-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-octyl group-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(3-trifluoromethyl-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-1-furans-2-ylmethyl-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-(4-chloro-benzyl)-4-[4-(3,5-two fluoro-benzyloxies)-benzyloxy]-5-oxo-2,5-dihydro-1H-pyrroles-3-carboxylic acid;
1-benzyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-pyrrolin-3-carboxylic acid;
4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-1-(3-trifluoromethyl-benzyl)-2,5-pyrrolin-3-carboxylic acid;
1-benzo [1,3] dioxolane-5-base-methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-pyrrolin-3-carboxylic acid;
1-cyclohexyl methyl-4-[4-(2,6-two chloro-benzyloxies)-aniline]-5-oxo-2,5-pyrrolin-3-carboxylic acid; With
4-[4-(2,6-two chloro-benzyloxies)-aniline]-1-octyl group-5-oxo-2,5-pyrrolin-3-carboxylic acid;
Or its pharmacologically acceptable salt or hydrate.
3. the preparation method of claim 1 general formula (I) compound,
For Q wherein is CH
2The formula of O (I) compound, this method may further comprise the steps:
(1) with R wherein
1As claim 1 general formula I define, X is the formula R of halogen
1CH
2X benzyl halide and p-Hydroxybenzaldehyde are raw material, handle in sodium hydride/DMF under-5-0 ℃ and stir 0.5 hour; In solvent such as methyl alcohol, reduce the scheme products therefrom with hydride reducer such as sodium borohydride then;
(2) under rare gas element such as nitrogen protection, make wherein R
2As the defined formula R of claim 1 general formula I
2CH
2Addition reaction takes place in X primary amine and ethyl propenoate under stirring at room, under reflux temperature condensation reaction takes place with oxalic acid diethyl ester in sodium ethylate-ethanol alkaline system then, make again product experience acidic hydrolysis;
(3) utilize catalyzer such as triphenyl phosphorus and diethylazodicarboxylate to make step (1) and step (2) product carry out condensation and slough 1 molecular water in solvent such as THF, and make it the saponification in solvent such as methyl alcohol with alkali such as sodium hydroxide, obtaining wherein, Q is CH
2O, R
1And R
2As the defined compound of Formula I of claim 1;
Perhaps,
For Q wherein is formula (I) compound of NH, and this method may further comprise the steps:
(1) under reflux temperature, make 2,6-dichloro bromobenzyl and paranitrobenzaldehyde react in sodium ethylate-ethanol alkaline system, then, reduce products therefrom with reductive agent such as tin protochloride in solvent such as ethanol;
(2) under rare gas element such as nitrogen protection, make wherein R
2As the defined formula R of claim 1 general formula I
2CH
2Addition reaction takes place in X primary amine and ethyl propenoate under stirring at room, under reflux temperature condensation reaction takes place with oxalic acid diethyl ester in sodium ethylate-ethanol alkaline system then, makes products therefrom experience acidic hydrolysis again;
(3) utilize catalyzer such as acetic acid to make the product condensation that step (1) and step (2) obtain and slough 1 molecular water, make it the saponification in solvent such as THF and ethanol with alkali such as sodium bicarbonate again, obtaining wherein, Q is NH, R
1And R
2As the defined general formula of claim 1 (I) compound.
4. pharmaceutical composition, it comprises according to the compound of Formula I of claim 1 or its all possible isomer or pharmacologically acceptable salt or hydrate, and at least a pharmaceutically acceptable carrier or vehicle.
5. the compound of Formula I of claim 1 is used to prepare the purposes for the treatment of fatty acid sythetase inhibitor.
6. the compound of Formula I of claim 1 is used to prepare the purposes of the medicine for the treatment of infectation of bacteria.
7. treat the method for infectation of bacteria, this method comprises formula (I) compound of the claim 1 that the patient treatment of these needs significant quantity is arranged.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101147935A CN101190894A (en) | 2006-11-23 | 2006-11-23 | Fatty acid synthetic enzyme inhibitor and medical preparation use thereof |
| PCT/CN2006/003402 WO2008061399A1 (en) | 2006-11-23 | 2006-12-13 | Fatty acid synthase inhibitor and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006101147935A CN101190894A (en) | 2006-11-23 | 2006-11-23 | Fatty acid synthetic enzyme inhibitor and medical preparation use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101190894A true CN101190894A (en) | 2008-06-04 |
Family
ID=39429367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006101147935A Pending CN101190894A (en) | 2006-11-23 | 2006-11-23 | Fatty acid synthetic enzyme inhibitor and medical preparation use thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101190894A (en) |
| WO (1) | WO2008061399A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101145612B1 (en) | 2009-12-14 | 2012-05-24 | 건국대학교 산학협력단 | A 4-[(5-Trifluoromethyl-pyridin-2-yl)-hydrazonomethyl]-benzene-1,3-diol, and a use as inhibitor of beta-Ketoacyl acyl carrier protein synthase III (KAS III) |
| HRP20191860T1 (en) | 2013-03-13 | 2019-12-27 | Forma Therapeutics, Inc. | 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer |
| TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
| WO2020092395A1 (en) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1546097A1 (en) * | 2002-09-20 | 2005-06-29 | Lupin Limited | Pyrrole derivatives as antimycobacterial compounds |
-
2006
- 2006-11-23 CN CNA2006101147935A patent/CN101190894A/en active Pending
- 2006-12-13 WO PCT/CN2006/003402 patent/WO2008061399A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008061399A1 (en) | 2008-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1210341B1 (en) | Compositions and therapeutic methods involving isoflavones and analogues thereof | |
| JPH0216315B2 (en) | ||
| US4624966A (en) | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound | |
| KR20190083674A (en) | Crystal form of quinoline compound and process for its production | |
| CN101190894A (en) | Fatty acid synthetic enzyme inhibitor and medical preparation use thereof | |
| CN104610359B (en) | It is a kind of to prepare key intermediate of Tedizolid Phosphate and preparation method thereof | |
| IE50475B1 (en) | Secondary amines,their preparation and use in pharmaceutical compositions | |
| WO1999002512A1 (en) | Dl-2,3-diaryl-2h-1-benzopyrans | |
| HU198918B (en) | Process for producing new epoxide derivatives | |
| US4843093A (en) | Butyrolactone derivatives, process for production thereof and use therefor | |
| JPS6319499B2 (en) | ||
| IE41563B1 (en) | Sulfonamides | |
| SU1205769A3 (en) | Method of producing dulcitol derivatives or salts thereof | |
| CN101190904A (en) | Fatty acid synthetic enzyme inhibitor and medical preparation use thereof | |
| US2915532A (en) | Synthesis of 3, 5-dihydroxy-3 methylpentanoic acid and the delta-lactone thereof | |
| JP3522790B2 (en) | H3-receptor stimulant | |
| CA2980221A1 (en) | Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof | |
| CN101117328B (en) | Fatty acid synthetase inhibitor and application for treating bacterial infection | |
| JPH06256278A (en) | Optically active alpha-carbamoylalkanoic acid derivative and its production | |
| US2753347A (en) | Dihydroqrotic acid | |
| KR100411205B1 (en) | Menthol derivatives and process for preparing the same | |
| US2753348A (en) | Dihydroorotic acid | |
| US2462449A (en) | Preparation of growth promoting substances | |
| JPH05194413A (en) | 5-nitro-1-methylimidazolyl-3-tert-butyl-2-hydroxyaryl- carbinol, production of its preparation and related therapeutic composition | |
| CN101434533A (en) | Novel preparation of sofalcone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080604 |